Tigecycline: A powerful antibiotic that fights resistant bacteria but carries a hidden risk
In short: Developed to combat the rise of multi-drug resistant bacteria, tigecycline is a potent glycylcycline antibiotic. While it effectively targets a broad spectrum of pathogens that defy traditional treatments, it is reserved for critical situations due to a serious FDA black box warning regarding an increased risk of patient mortality.
Tigecycline, known by the brand name Tygacil, represents a significant evolution in the tetracycline class. First synthesized as GAR-936 in 1999, it was approved by the FDA in June 2005. Its unique structure—a 9-dimethylglycylamido derivative of minocycline—allows it to bind to the 30S ribosomal subunit of bacteria with significantly higher affinity than its predecessors. This mechanism enables it to bypass common resistance pathways, making it effective against formidable pathogens like MRSA and various multi-drug resistant Gram-negative organisms.
Despite its clinical efficacy in treating complicated skin, soft tissue, and intra-abdominal infections, the drug is not without controversy. In 2010, the FDA issued a black box warning after data indicated a numerically higher mortality rate in patients treated with tigecycline compared to other antibiotics. Although the exact cause of this increased risk remains unknown, the warning was updated in 2013, effectively relegating the drug to a last-resort status for when alternative treatments are unsuitable. It is not indicated for patients with infections caused by Pseudomonas spp. or Proteus spp., which are naturally resistant.
Beyond its primary role as an antibiotic, tigecycline has garnered interest for its potential non-antibiotic properties. Research suggests it may inhibit mitochondrial protein translation in eukaryotic cells, showing promise in vitro and in vivo against various cancers, including acute myeloid leukemia and glioblastoma. While these findings highlight the drug's versatility, its clinical use remains strictly regulated. It is generally well-tolerated, though gastrointestinal side effects like nausea and vomiting are common, and it carries specific risks for pregnant women and children, such as potential tooth discoloration and impaired bone development.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Tigecycline
To cite this card, link to https://intellectplus.co.uk/app/health-tigecycline.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Drugs and medication · More in Health · Latest · A–Z · All topics
